Temocillin vs Meropenem for the Targeted Treatment of Bacteraemia Resistant to Third Gen Cephalosporins

Launched by FUNDACIÓN PÚBLICA ANDALUZA PARA LA GESTIÓN DE LA INVESTIGACIÓN EN SEVILLA · Jul 15, 2020

Keywords

ClinConnect Summary

This clinical trial is studying the effectiveness of two antibiotics, temocillin and meropenem, in treating a serious infection called bacteremia, which is caused by bacteria in the bloodstream. The trial is specifically looking at patients whose infections are resistant to certain common antibiotics but still respond to temocillin and meropenem. Researchers want to see if temocillin is just as effective as meropenem in treating these infections.

To participate in this study, you must be an adult between the ages of 18 and 74 who has a specific type of bacteremia caused by certain bacteria. You'll need to be able to give consent to participate and meet other criteria related to your health. If you join, you'll receive treatment for 7 to 14 days, with the possibility of switching to an oral form of the medication after the first few days if your condition allows. It's important to note that some individuals, such as pregnant or breastfeeding women and those with certain severe health conditions, will not be eligible to participate. This trial is currently recruiting participants, and your involvement could help researchers find better treatments for this challenging infection.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adult patients with monomicrobial bacteremia due to Enterobacteriaceae showing resistance to cefotaxime, ceftriaxone (MIC \>2 mg/L) and/or ceftazidime (MIC \>4 mg/L), and sensible to temocillin (MIC ≤8 mg/L, except in bacteremia only of urinary origin, for which the criterion is MIC ≤16 mg/L ) and meropenem (MIC ≤2 mg/L).
• • Duration of intravenous treatment is planned to be at least 4 days.
• • The patient signed informed consent form.
• Exclusion Criteria:
• • \<18 years
• • Pregnancy
• • Breastfeeding
• • Palliative care
• • Allergy to betalactams
• • Polymicrobial bacteraemia
• • Infections typically needing prolonged \>14 days of therapy (e.g., endocarditis, prosthetic joint infection, vascular graft infection, empyema, chronic prostatitis) or meningitis
• • Active empirical treatment\> 96 hours after initial blood culture extraction
• • Delay in inclusion\> 48 h
• • Recruited in another clinical trial with active treatment
• • Peritoneal dialysis or continuous hemofiltration
• • extreme gravity or imminent death